PriceTargets.com logo

Dyadic International - DYAI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 238.98%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.77 As of 12/1/2023 01:00 AM ET
▲ +0.08 (4.73%)

This chart shows the closing price for DYAI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dyadic International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DYAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DYAI

Analyst Price Target is $6.00
▲ +238.98% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Dyadic International in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 238.98% upside from the last price of $1.77.

This chart shows the closing price for DYAI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Dyadic International. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
2/3/2023HC WainwrightReiterated RatingBuy$6.00Low
7/18/2022Dawson JamesDowngradeBuy ➝ NeutralLow
4/4/2022HC WainwrightLower TargetBuy$7.00 ➝ $6.00High
1/11/2022HC WainwrightReiterated RatingBuy$7.00Low
12/29/2021HC WainwrightReiterated RatingBuy$7.00Low
12/17/2021HC WainwrightInitiated CoverageBuy$7.00High
8/14/2020Noble FinancialReiterated RatingBuy$11.00High
6/29/2020Noble FinancialReiterated RatingBuy$11.00Medium
6/10/2020Noble FinancialReiterated RatingBuy$11.00High
5/19/2020Noble FinancialReiterated RatingBuy$11.00Low
2/26/2020Noble FinancialReiterated RatingBuy$11.00High
2/26/2020Dawson JamesReiterated RatingBuyHigh
1/29/2020Noble FinancialReiterated RatingBuy$11.00Low
10/16/2019Dawson JamesInitiated CoverageBuy$14.00Low
7/8/2019Noble FinancialReiterated RatingBuy$9.00Medium
5/12/2019Noble FinancialReiterated RatingBuy$9.00High
5/1/2019Noble FinancialReiterated RatingBuy$4.00Medium
1/7/2019Noble FinancialInitiated CoverageOutperformLow
(Data available from 12/3/2018 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2023
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2023
  • 5 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2023
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2023

Current Sentiment

  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Dyadic International logo
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design,Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.
Read More

Today's Range

Now: $1.77
Low: $1.65
High: $1.80

50 Day Range

MA: $1.78
Low: $1.53
High: $2.08

52 Week Range

Now: $1.77
Low: $1.12
High: $2.40

Volume

47,513 shs

Average Volume

21,528 shs

Market Capitalization

$50.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Dyadic International?

The following Wall Street analysts have issued stock ratings on Dyadic International in the last year: HC Wainwright.
View the latest analyst ratings for DYAI.

What is the current price target for Dyadic International?

1 Wall Street analysts have set twelve-month price targets for Dyadic International in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 239.0%. HC Wainwright has the highest price target set, predicting DYAI will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Dyadic International in the next year.
View the latest price targets for DYAI.

What is the current consensus analyst rating for Dyadic International?

Dyadic International currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DYAI will outperform the market and that investors should add to their positions of Dyadic International.
View the latest ratings for DYAI.

What other companies compete with Dyadic International?

Other companies that are similar to Dyadic International include Aligos Therapeutics, Precision BioSciences, Estrella Immunopharma, SAB Biotherapeutics and OKYO Pharma. Learn More about companies similar to Dyadic International.

How do I contact Dyadic International's investor relations team?

Dyadic International's physical mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The biotechnology company's listed phone number is (561) 743-8333 and its investor relations email address is praws[email protected]. The official website for Dyadic International is www.dyadic.com. Learn More about contacing Dyadic International investor relations.